查找临床试验

已按「荨麻疹」检索,对应国际通用词 chronic urticaria

试验不在中国怎么办?

共找到 10 项正在招募的试验(在中国/港澳台设有中心)

数据更新于 00:19,每 5 分钟自动同步
正在招募II 期 / III 期中国有中心NCT06924762

Interleukin-2 for Refractory Chronic Spontaneous Urticaria

China

年龄 18 Years – 74 Years

Second Xiangya Hospital of Central South University

正在招募II 期中国有中心NCT07219615

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

United States、Bulgaria、Canada、China、Germany 等 10 国

年龄 18 Years – 不限

Pfizer

正在招募II 期中国有中心NCT07415551

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

Bulgaria、China、Poland、South Korea

年龄 18 Years – 75 Years

Yuhan Corporation

正在招募III 期中国有中心NCT07816328

Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks

Hong Kong、Japan、South Korea

年龄 18 Years – 不限

Novartis Pharmaceuticals

正在招募II 期 / III 期中国有中心NCT07378527

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

China

年龄 18 Years – 75 Years

Beijing InnoCare Pharma Tech Co., Ltd.

正在招募III 期中国有中心NCT07402213

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

China

年龄 18 Years – 不限

Jemincare

正在招募I 期中国有中心NCT07005713

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

China

年龄 18 Years – 70 Years

BeOne Medicines

正在招募II 期中国有中心NCT06509334

Trial of JYB1904 in Chronic Spontaneous Urticaria.

China

年龄 18 Years – 不限

Jemincare

正在招募II 期中国有中心NCT07166211

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

China

年龄 18 Years – 75 Years

Keymed Biosciences Co.Ltd

正在招募I 期 / II 期中国有中心NCT07717905

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

China

年龄 18 Years – 75 Years

Bambusa Therapeutics